Liraglutide, a glucagon-like peptide-1 analog, increased insulin sensitivity assessed by hyperinsulinemic-euglycemic clamp examination in patients with uncontrolled type 2 diabetes mellitus

Journal of Diabetes Research

Volumn 2015, Issue , 2015, Pages

  Jinnouchi, Hideaki ^a,b   Sugiyama, Seigo ^a,c   Yoshida, Akira ^a   Hieshima, Kunio ^a   Kurinami, Noboru ^a   Suzuki, Tomoko ^a   Miyamoto, Fumio ^a   Kajiwara, Keizo ^a   Matsui, Kunihiko ^b   Jinnouchi, Tomio ^a  

^a Jinnouchi Clinic   (Japan)

^b KUMAMOTO UNIVERSITY HOSPITAL   (Japan)

^c KUMAMOTO UNIVERSITY   (Japan)

Author keywords

[No Author keywords available]

Indexed keywords

HEMOGLOBIN A1C; INSULIN ASPART; INSULIN DEGLUDEC; INSULIN GLARGINE; INSULIN GLULISINE; INSULIN LISPRO; LIRAGLUTIDE; GLUCAGON LIKE PEPTIDE 1; GLUCOSE; GLYCOSYLATED HEMOGLOBIN; HEMOGLOBIN A1C PROTEIN, HUMAN; INSULIN;

ADULT; ARTICLE; BODY MASS; CLINICAL ARTICLE; CONTROLLED STUDY; DIET; FEMALE; GLUCOSE BLOOD LEVEL; GLUCOSE CLAMP TECHNIQUE; GLUCOSE INFUSION; HUMAN; HYPERINSULINEMIC EUGLYCEMIC CLAMP; INFUSION RATE; INSULIN SENSITIVITY; INSULIN TREATMENT; KINESIOTHERAPY; MALE; MULTIPLE CYCLE TREATMENT; NON INSULIN DEPENDENT DIABETES MELLITUS; PRIORITY JOURNAL; PROSPECTIVE STUDY; AGED; ANALOGS AND DERIVATIVES; BLOOD; DIABETES MELLITUS, TYPE 2; DIET THERAPY; EXERCISE; HOSPITALIZATION; HYPERINSULINISM; LIFESTYLE; METABOLISM; MIDDLE AGED; MULTIVARIATE ANALYSIS; PANCREAS ISLET BETA CELL;

AGED; DIABETES MELLITUS, TYPE 2; DIET; DIET THERAPY; EXERCISE; FEMALE; GLUCAGON-LIKE PEPTIDE 1; GLUCOSE; GLUCOSE CLAMP TECHNIQUE; HEMOGLOBIN A, GLYCOSYLATED; HOSPITALIZATION; HUMANS; HYPERINSULINISM; INSULIN; INSULIN-SECRETING CELLS; LIFE STYLE; LIRAGLUTIDE; MALE; MIDDLE AGED; MULTIVARIATE ANALYSIS; PROSPECTIVE STUDIES;

EID: 84928255405     PISSN: 23146745     EISSN: 23146753     Source Type: Journal    
DOI: 10.1155/2015/706416     Document Type: Article

References (28)

1. S. E. Inzucchi, R. M. Bergenstal, J. B. Buse et al., "Management of hyperglycemia in type 2 diabetes: a patient-centered approach: position statement of the American Diabetes Association (ADA) and the European Association for the Study of Diabetes (EASD)," Diabetes care, vol. 35, no. 6, pp. 1364-1379, 2012.
2. J. A. Lovshin and D. J. Drucker, "Incretin-based therapies for type 2 diabetes mellitus," Nature Reviews Endocrinology, vol. 5, no. 5, pp. 262-269, 2009.
3. D. J. Drucker andM. A. Nauck, "The incretin system: glucagonlike peptide-1 receptor agonists and dipeptidyl peptidase-4 inhibitors in type 2 diabetes," The Lancet, vol. 368, no. 9548, pp. 1696-1705, 2006.
4. Y. Seino and D. Yabe, "Glucose-dependent insulinotropic polypeptide and glucagon-like peptide-1: incretin actions beyond the pancreas," Journal of Diabetes Investigation, vol. 4, no. 2, pp. 108-130, 2013.
5. T. Vilsbøll,M. Christensen, A. E. Junker, F. K. Knop, and L. L. Gluud, "Effects of glucagon-like peptide-1 receptor agonists on weight loss: systematic reviewandmeta-analyses of randomised controlled trials," British Medical Journal, vol. 344, no. 7841, Article ID d7771, 2012.
6. B. Vergès, C. Bonnard, and E. Renard, "Beyond glucose lowering: Glucagon-like peptide-1 receptor agonists, body weight and the cardiovascular system," Diabetes & Metabolism, vol. 37, no. 6, pp. 477-488, 2011.
7. P. Grigoropoulou, I. Eleftheriadou, C. Zoupas, E. Diamanti-Kandarakis, and N. Tentolouris, "Incretin-based therapies for type 2 diabetes mellitus: effects on insulin resistance," Current Diabetes Reviews, vol. 9, no. 5, pp. 412-417, 2013.
8. N. M. Krasner, Y. Ido, N. B. Ruderman, and J. M. Cacicedo, "Glucagon-Like Peptide-1 (GLP-1) analog liraglutide inhibits endothelial cell inflammation through a calcium and AMPK dependent mechanism," PLoS ONE, vol. 9, no. 5, Article ID e97554, 2014.
9. S. Yamazaki, H. Satoh, and T. Watanabe, "Liraglutide enhances insulin sensitivity by activating AMP-activated protein kinase in male wistar rats," Endocrinology, vol. 155, no. 9,pp. 3288-3301, 2014.
10. M. Zander, S. Madsbad, J. L. Madsen, and J. J. Holst, "Effect of 6-week course of glucagon-like peptide 1 on glycaemic control, insulin sensitivity, and-cell function in type 2 diabetes: a parallel-group study," The Lancet, vol. 359, no. 9309, pp. 824-830, 2002.
11. J. M. Egan, G. S. Meneilly, and D. Elahi, "Effects of 1-mo bolus subcutaneous administration of exendin-4 in type 2 diabetes," The American Journal of Physiology-Endocrinology and Metabolism, vol. 284, no. 6, pp. E1072-E1079, 2003.
12. M. C. Bunck, M. Diamant, A. Cornér et al., "One-year treatment with exenatide improves beta-cell function, compared with insulin glargine, in metformin-treated type 2 diabetic patients: a randomized, controlled trial," Diabetes Care, vol. 32, no. 5, pp. 762-768, 2009.
13. R. A. DeFronzo, C. Triplitt, Y. Qu,M. S. Lewis, D. Maggs, and L. C. Glass, "Effects of exenatide plus rosiglitazone on-cell function and insulin sensitivity in subjects with type 2 diabetes on metformin," Diabetes Care, vol. 33, no. 5, pp. 951-957, 2010.
14. S. Sugiyama, H. Jinnouchi, K. Hieshima, and T. Jinnouchi, "Insulin supersensitivity and normoinsulinaemic hypoglycaemia in uncontrolled type 2 diabetes mellitus: clinical usefulness of 3 h assessment in the 75 g oral glucose tolerance test," BMJ Case Reports, Article ID bcr2013201908, 2014.
15. R. A. DeFronzo, J. D. Tobin, and R. Andres, "Glucose clamp technique: a method for quantifying insulin secretion and resistance,"The American Journal of Physiology, vol. 237, no. 3, pp. E214-E223, 1979.
16. J. Joya-Galeana, M. Fernandez, A. Cervera et al., "Effects of insulin and oral anti-diabetic agents on glucose metabolism, vascular dysfunction and skeletal muscle inflammation in type 2 diabetic subjects," Diabetes/MetabolismResearch and Reviews, vol. 27, no. 4, pp. 373-382, 2011.
17. D. E. Rosenberg, S. A. Jabbour, and B. J. Goldstein, "Insulin resistance, diabetes and cardiovascular risk: approaches to treatment," Diabetes, Obesity and Metabolism, vol. 7, no. 6, pp. 642-653, 2005.
18. F. Paneni, S. Costantino, and F. Cosentino, "Insulin resistance, diabetes, and cardiovascular risk," Current Atherosclerosis Reports, vol. 16, article 419, 2014.
19. K. Inoue, N. Maeda, S. Kashine et al., "Short-term effects of liraglutide on visceral fat adiposity, appetite, and food preference: a pilot study of obese Japanese patients with type 2 diabetes," Cardiovascular Diabetology, vol. 10, article 109, 2011.
20. S. Del Prato, "Role of glucotoxicity and lipotoxicity in the pathophysiology of Type 2 diabetes mellitus and emerging treatment strategies," DiabeticMedicine, vol. 26,no. 12,pp. 1185-1192, 2009.
21. L.-N. Chen, J. Lyu, X.-F. Yang et al., "Liraglutide ameliorates glycometabolism and insulin resistance through the upregulation of GLUT4 in diabetic KKAy mice," International Journal of Molecular Medicine, vol. 32, no. 4, pp. 892-900, 2013.
22. A. Shiraki, J.-I. Oyama, H. Komoda et al., "The glucagon-like peptide 1 analog liraglutide reduces TNF-induced oxidative stress and inflammation in endothelial cells," Atherosclerosis, vol. 221, no. 2, pp. 375-382, 2012.
23. K. Okada, K. Kotani, H. Yagyu, A. Ando, J.-I. Osuga, and S. Ishibashi, "Effects of treatment with liraglutide on oxidative stress and cardiac natriuretic peptide levels in patients with type 2 diabetes mellitus," Endocrine, vol. 47, no. 3, pp. 962-964, 2014.
24. Y.-S. Lee, M.-S. Park, J.-S. Choung et al., "Glucagon-like peptide-1 inhibits adipose tissue macrophage infiltration and inflammation in an obese mouse model of diabetes," Diabetologia, vol. 55, no. 9, pp. 2456-2468, 2012.
25. T. Gaspari, H. Liu, I. Welungoda et al., "AGLP-1 receptor agonist liraglutide inhibits endothelial cell dysfunction and vascular adhesion molecule expression in an ApoE-/-mouse model," Diabetes and Vascular Disease Research, vol. 8, no. 2, pp. 117-124, 2011.
26. M. H. Noyan-Ashraf, E. A. Shikatani, I. Schuiki et al., "A glucagon-like peptide-1 analog reverses the molecular pathology and cardiac dysfunction of a mouse model of obesity," Circulation, vol. 127, no. 1, pp. 74-85, 2013.
27. C. B. Juhl, M. Hollingdal, J. Sturis et al., "Bedtime administration of NN2211, a long-acting GLP-1 derivative, substantially reduces fasting and postprandial glycemia in type 2 diabetes," Diabetes, vol. 51, no. 2, pp. 424-429, 2002.
28. K. B. Degn, C. B. Juhl, J. Sturis et al., "One week's treatmentwith the long-acting glucagon-like peptide 1 derivative liraglutide (NN2211) markedly improves 24-h glycemia and-and-cell function and reduces endogenous glucose release in patients with type 2 diabetes," Diabetes, vol. 53,no. 5, pp. 1187-1194, 2004.